Is SRRK or TARS more undervalued in 2026?

CirclFi compares Scholar Rock Holding Corporatio (SRRK) and Tarsus Pharmaceuticals, Inc. (TARS) using 13 institutional-grade valuation models. SRRK has a Quality of Company score of 5.1/10 while TARS scores 6.2/10.

Which is a better buy — SRRK or TARS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do SRRK and TARS valuations compare?

SRRK at $49.30 and TARS at $59.40 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

SRRK vs TARS Valuation Comparison 2026 — Intrinsic Value Analysis

SRRK

Biological Products, (No Diagnostic Substances)

Scholar Rock Holding Corporatio

Quality

5.1

out of 10

Value Trap

LOW

Price

$49.30

Last close

Models

10/13

Active

TARS

Biological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc.

Quality

6.2

out of 10

Value Trap

SAFE

Price

$59.40

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	SRRK Fair Value	SRRK Upside	TARS Fair Value	TARS Upside
Bayesian DCF	Intrinsic	$15.50	-68.6%	$13.82	-76.7%
Earnings Power Value	Intrinsic	$21.36	-54.0%	$27.01	-56.0%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for SRRK vs TARS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

SRRK vs TARS — Which Stock Is More Undervalued?

TARS scores higher with a 6.2/10 quality rating vs SRRK's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Scholar Rock Holding Corporatio (SRRK) and Tarsus Pharmaceuticals, Inc. (TARS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

SRRK currently trades at $49.30 with a QOC of 5.1/10, while TARS trades at $59.40 with a QOC of 6.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).